Todd A Lee

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8913696/publications.pdf

Version: 2024-02-01

57758 42399 9,338 180 44 92 citations h-index g-index papers 180 180 180 12056 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Development of a measure of prescriber satisfaction with academic detailing: the PSAD. Drugs in Context, 2022, 11, 1-12.	2.2	2
2	Trends in Opioid Prescribing by General Dentists and Dental Specialists in the U.S., 2012–2019. American Journal of Preventive Medicine, 2022, 63, 3-12.	3.0	8
3	Barriers to and facilitators of opioid prescribing by dentists in the United States. Journal of the American Dental Association, 2022, , .	1.5	O
4	Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in Pharmacovigilance. Therapeutic Innovation and Regulatory Science, 2021, 55, 142-151.	1.6	4
5	Network meta-analysis of infliximab biosimilars for the treatment of rheumatoid arthritis. American Journal of Health-System Pharmacy, 2021, 78, 697-704.	1.0	5
6	Secondary Effects of an Opioid-Focused Academic Detailing Program on Non-Opioid Controlled Substance Prescribing in Primary Care. Substance Abuse, 2021, 42, 962-967.	2.3	1
7	Racial Disparities in Intravenous Bisphosphonate Use Among Older Patients With Multiple Myeloma Enrolled in Medicare. JCO Oncology Practice, 2021, 17, e294-e312.	2.9	7
8	Feasibility and acceptability of virtual academic detailing on opioid prescribing. International Journal of Medical Informatics, 2021, 147, 104365.	3.3	10
9	Trend in Tyrosine Kinase Inhibitor Utilization, Price, and Out-of-Pocket Costs in Patients With Chronic Myelogenous Leukemia. JCO Oncology Practice, 2021, 17, e1811-e1820.	2.9	8
10	Hospitalizations for opioidâ€related overdose and timing of concurrent opioid and benzodiazepine use: A nested caseâ€control study. Pharmacotherapy, 2021, 41, 722-732.	2.6	2
11	Risk of fallâ€related injury and allâ€cause hospitalization of select concomitant central nervous system medication prescribing in older adult persistent opioid users: A caseâ€timeâ€control analysis. Pharmacotherapy, 2021, 41, 733-742.	2.6	1
12	Combating the opioid epidemic in the United States. Drugs in Context, 2021, 10, 1-3.	2.2	2
13	Antidiabetic drug use trends in patients with type 2 diabetes mellitus and chronic kidney disease: A crossâ€sectional analysis of the National Health and Nutrition Examination Survey. Journal of Diabetes, 2020, 12, 385-395.	1.8	13
14	Hospitalization and emergency department utilization in patients with advanced melanoma receiving pembrolizumab versus ipilimumab plus nivolumab in US academic centers. Journal of Medical Economics, 2020, 23, 132-138.	2.1	6
15	Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 67-75.	0.9	6
16	Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance. Expert Opinion on Drug Safety, 2020, 19, 1357-1366.	2.4	4
17	Practice change intentions after academic detailing align with subsequent opioid prescribing. Journal of the American Pharmacists Association: JAPhA, 2020, 60, 1001-1008.	1.5	7
18	Risk of cardiac events with azithromycinâ€"A prediction model. PLoS ONE, 2020, 15, e0240379.	2.5	0

#	Article	IF	CITATIONS
19	Comparison of Cardiac Events Associated With Azithromycin vs Amoxicillin. JAMA Network Open, 2020, 3, e2016864.	5.9	6
20	Identification of barriers to safe opioid prescribing in primary care: a qualitative analysis of field notes collected through academic detailing. British Journal of General Practice, 2020, 70, e589-e597.	1.4	12
21	Targets of biologic diseaseâ€modifying antirheumatic drugs and risk of multiple myeloma. International Journal of Cancer, 2020, 147, 1300-1305.	5.1	6
22	Risk of cardiac events with azithromycinâ€"A prediction model. , 2020, 15, e0240379.		0
23	Risk of cardiac events with azithromycinâ€"A prediction model. , 2020, 15, e0240379.		0
24	Risk of cardiac events with azithromycinâ€"A prediction model. , 2020, 15, e0240379.		0
25	Risk of cardiac events with azithromycinâ€"A prediction model. , 2020, 15, e0240379.		0
26	Older Medicare Beneficiaries Frequently Continue Medications with Limited Benefit Following Hospice Admission. Journal of General Internal Medicine, 2019, 34, 2029-2037.	2.6	10
27	Sodiumâ€glucose coâ€transporter 2 inhibitors and the risk of fractures: A propensity scoreâ€matched cohort study. Pharmacoepidemiology and Drug Safety, 2019, 28, 1629-1639.	1.9	21
28	Use of Nonpalliative Medications Following Burdensome Health Care Transitions in Hospice Patients. Medical Care, 2019, 57, 13-20.	2.4	6
29	Increased risk of mycotic infections associated with sodium–glucose coâ€transporter 2 inhibitors: a prescription sequence symmetry analysis. British Journal of Clinical Pharmacology, 2019, 85, 160-168.	2.4	22
30	Health care resource utilization in patients with advanced melanoma receiving immunotherapies in the real world Journal of Clinical Oncology, 2019, 37, 9532-9532.	1.6	1
31	Medicare Part D Use of Older Medicare Beneficiaries Admitted to Hospice. Journal of the American Geriatrics Society, 2018, 66, 937-944.	2.6	6
32	Tumor necrosis factorâ€alpha inhibitors and risk of nonâ€Hodgkin lymphoma in a cohort of adults with rheumatologic conditions. International Journal of Cancer, 2018, 143, 1062-1071.	5.1	42
33	The impact of depression medications on oral antidiabetic drug adherence in patients with diabetes and depression. Journal of Diabetes and Its Complications, 2018, 32, 492-500.	2.3	6
34	Risk of Serious Bacterial Infection Associated With Tumor Necrosis Factor–Alpha Inhibitors in Children and Young Adults With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 883-891.	1.9	9
35	Risk of serious bacterial infection associated with tumour necrosis factor-alpha inhibitors in children with juvenile idiopathic arthritis. Rheumatology, 2018, 57, 273-282.	1.9	23
36	Parallel Valuation: A Direct Comparison of EQ-5D-3L and EQ-5D-5L Societal Value Sets. Medical Decision Making, 2018, 38, 968-982.	2.4	25

#	Article	IF	CITATIONS
37	Predicting Acute Exacerbations in Chronic Obstructive Pulmonary Disease. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 265-279.	0.9	8
38	Risk of amputations associated with SGLT2 inhibitors compared to DPPâ€4 inhibitors: A propensityâ€matched cohort study. Diabetes, Obesity and Metabolism, 2018, 20, 2792-2799.	4.4	52
39	Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome. Journal of Managed Care & Decialty Pharmacy, 2018, 24, 800-812.	0.9	3
40	Risk of Diabetes Hospitalization or Diabetes Drug Intensification in Patients With Depression and Diabetes Using Second-Generation Antipsychotics Compared to Other Depression Therapies. primary care companion for CNS disorders, The, 2018, 20, .	0.6	3
41	Venous Thromboembolic Prophylaxis Following Treatment Initiation for Multiple Myeloma. Blood, 2018, 132, 4693-4693.	1.4	O
42	Biologic Disease-Modifying Antirheumatic Drugs and Risk of Multiple Myeloma. Blood, 2018, 132, 1888-1888.	1.4	0
43	A Review of the Utility and Cost Effectiveness of Monitoring Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. Managed Care, 2018, 27, 34-41.	0.3	8
44	Comparative Effectiveness of Long-Acting Beta ₂ -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease. Pharmacotherapy, 2017, 37, 447-455.	2.6	18
45	Reply: Association Between Proton Pump Inhibitors and Microscopic Colitis: Implications for Practice and Future Research. Annals of Pharmacotherapy, 2017, 51, 719-719.	1.9	13
46	Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome. Pharmacotherapy, 2017, 37, 877-887.	2.6	7
47	Patient Experience-based Value Sets. Medical Care, 2017, 55, 979-984.	2.4	10
48	High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy. Journal of Thrombosis and Thrombolysis, 2017, 44, 435-441.	2.1	22
49	Realâ€World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation. Pharmacotherapy, 2017, 37, 1221-1230.	2.6	74
50	Increased Risk of Diabetes Among 6–24-Year-Olds Using Second Generation Antipsychotics. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 782-791.	1.3	2
51	Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting \hat{l}^2 2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid. Annals of Pharmacotherapy, 2017, 51, 945-953.	1.9	19
52	Association Between Proton Pump Inhibitors and Microscopic Colitis. Annals of Pharmacotherapy, 2017, 51, 253-263.	1.9	39
53	Ceftriaxone-Associated Biliary and Cardiopulmonary Adverse Events in Neonates: A Systematic Review of the Literature. Paediatric Drugs, 2017, 19, 21-34.	3.1	28
54	Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome. Journal of Managed Care & Decialty Pharmacy, 2017, 23, 57-63.	0.9	29

#	Article	IF	CITATIONS
55	The societal cost of heroin use disorder in the United States. PLoS ONE, 2017, 12, e0177323.	2.5	48
56	Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data. Annals of the American Thoracic Society, 2016, 13, 1067-1075.	3.2	16
57	Comparison of Health Care Utilization and Costs for Patients with Asthma by Severity and Health Insurance in Thailand. Value in Health Regional Issues, 2016, 9, 105-111.	1.2	12
58	Statin and Aspirin Use Among Hispanic and Latino Adults at High Cardiovascular Risk: Findings From the Hispanic Community Health Study/Study of Latinos. Journal of the American Heart Association, 2016, 5, e002905.	3.7	16
59	Sensitization to mouse and cockroach allergens and asthma morbidity in urban minority youth. Annals of Allergy, Asthma and Immunology, 2016, 117, 43-49.e1.	1.0	15
60	Use of Tumor Necrosis Factor-Alpha Inhibitors in Children and Young Adults With Juvenile Idiopathic Arthritis or Rheumatoid Arthritis. Pharmacotherapy, 2016, 36, 1201-1209.	2.6	10
61	Top-down Versus Step-up Prescribing Strategies for Tumor Necrosis Factor Alpha Inhibitors in Children and Young Adults with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 2410-2417.	1.9	15
62	Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective. Lancet Respiratory Medicine, the, 2016, 4, 473-526.	10.7	80
63	Using linked electronic data to validate algorithms for health outcomes in administrative databases. Journal of Comparative Effectiveness Research, 2015, 4, 359-366.	1.4	2
64	Drug–Alcohol Interactions in Older U.S. Adults. Journal of the American Geriatrics Society, 2015, 63, 2324-2331.	2.6	34
65	Tumor Necrosis Factor-Alpha Inhibitor Medications for Inflammatory Conditions and Incidence of Multiple Myeloma. Blood, 2015, 126, 2954-2954.	1.4	1
66	Home-based Diagnosis of Obstructive Sleep Apnea in an Urban Population. Journal of Clinical Sleep Medicine, 2014, 10, 879-885.	2.6	62
67	Cost-utility of chelators in transfusion-dependent \hat{l}^2 -thalassemia major patients: a review of the pharmacoeconomic literature. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 651-660.	1.4	4
68	Understanding medication oversupply and its predictors in the outpatient departments in Thailand. BMC Health Services Research, 2014, 14, 408.	2.2	7
69	Coexisting chronic conditions associated with mortality and morbidity in adult patients with asthma. Journal of Asthma, 2014, 51, 306-314.	1.7	44
70	Calendar timeâ€specific propensity score analysis for observational data: a case study estimating the effectiveness of inhaled longâ€acting betaâ€agonist on asthma exacerbations. Pharmacoepidemiology and Drug Safety, 2014, 23, 152-164.	1.9	6
71	Capitalizing on Prescribing Pattern Variation to Compare Medications for Type 2 Diabetes. Value in Health, 2014, 17, 854-862.	0.3	17
72	Drugs Associated with Adverse Events in Children and Adolescents. Pharmacotherapy, 2014, 34, 918-926.	2.6	21

#	Article	IF	CITATIONS
73	Multicenter Study Comparing Case Definitions Used to Identify Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 989-995.	5.6	47
74	Outcomes of ceftriaxone use compared to standard of therapy in methicillin susceptible staphylococcal aureus (MSSA) bloodstream infections. International Journal of Clinical Pharmacy, 2014, 36, 1282-1289.	2.1	30
75	Association Between Chronic Illness Complexity and Receipt of Evidence-based Depression Care. Medical Care, 2014, 52, S126-S131.	2.4	7
76	â€~Pharmacy Deserts' Are Prevalent In Chicago's Predominantly Minority Communities, Raising Medication Access Concerns. Health Affairs, 2014, 33, 1958-1965.	5.2	141
77	Thiazide Use Is Associated With Reduced Risk for Incident Lower Extremity Fractures in Men With Spinal Cord Injury. Archives of Physical Medicine and Rehabilitation, 2014, 95, 1015-1020.	0.9	11
78	Outpatient influenza antiviral prescription trends with influenza-like illness in the USA, 2008–2010. International Journal of Antimicrobial Agents, 2014, 43, 279-283.	2.5	3
79	Risk of Arrhythmias Associated with Ipratropium Bromide in Children, Adolescents, and Young Adults with Asthma: A Nested Caseâ€Control Study. Pharmacotherapy, 2014, 34, 315-323.	2.6	12
80	The risk of seizures among the carbapenems: a meta-analysis. Journal of Antimicrobial Chemotherapy, 2014, 69, 2043-2055.	3.0	84
81	Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review. Pharmacoeconomics, 2014, 32, 1079-1091.	3.3	18
82	Measuring health-related quality of life in chronic obstructive pulmonary disease: properties of the EQ-5D-5L and PROMIS-43 short form. BMC Medical Research Methodology, 2014, 14, 78.	3.1	46
83	Reply. Journal of Vascular Surgery, 2014, 59, 876.	1.1	3
84	Comparative Analysis of Calendar Time-Specific and Conventional Propensity Score Analysis for Thiazolidinedione Use in Diabetes. Value in Health Regional Issues, 2014, 3, 222-228.	1.2	0
85	Statin use and lower extremity amputation risk in nonelderly diabetic patients. Journal of Vascular Surgery, 2013, 58, 1578-1585.e1.	1.1	42
86	Development, validation, and results of a riskâ€standardized measure of hospital 30â€day mortality for patients with exacerbation of chronic obstructive pulmonary disease. Journal of Hospital Medicine, 2013, 8, 428-435.	1.4	34
87	Use of Spirometry in the Diagnosis of COPD: A Qualitative Study in Primary Care. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 444-449.	1.6	49
88	The association of opioid use with incident lower extremity fractures in spinal cord injury. Journal of Spinal Cord Medicine, 2013, 36, 91-96.	1.4	37
89	Stakeholder Priorities for Comparative Effectiveness Research in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 320-326.	5.6	38
90	Medication acquisition across systems of care and patient–provider communication among older veterans. American Journal of Health-System Pharmacy, 2013, 70, 804-813.	1.0	26

#	Article	IF	Citations
91	The Association of Anticonvulsant Use with Fractures in Spinal Cord Injury. American Journal of Physical Medicine and Rehabilitation, 2013, 92, 1037-1050.	1.4	19
92	Appropriateness of Medication Prescribing Using the STOPP/START Criteria in Veterans Receiving Home-Based Primary Care. The Consultant Pharmacist, 2013, 28, 361-369.	0.4	12
93	Lung and colon cancer costs among chemotherapy patients after an FDA policy change Journal of Clinical Oncology, 2013, 31, e14578-e14578.	1.6	0
94	The Validity of International Classification of Diseases, Ninth Revision, Clinical Modification Diagnosis Codes for Identifying Patients Hospitalized for COPD Exacerbations. Chest, 2012, 141, 87-93.	0.8	122
95	Comparative effectiveness research in chronic obstructive pulmonary disease. Journal of Comparative Effectiveness Research, 2012, 1, 71-82.	1.4	11
96	Reduced Overall and Event-Free Survival among Colon Cancer Patients Using Dual System Care. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2231-2241.	2.5	35
97	The Association Between Leukotriene-Modifying Agents and Spontaneously Reported Suicide. Drug Information Journal, 2012, 46, 99-106.	0.5	6
98	Evaluation of changes in guidelines for medication management of stable chronic obstructive pulmonary disease. Journal of Evaluation in Clinical Practice, 2012, 19, n/a-n/a.	1.8	4
99	Hemoglobin Levels Triggering Erythropoiesisâ€Stimulating Agent Therapy in Patients with Cancer: the Shift After United States Food and Drug Administration Policy Changes. Pharmacotherapy, 2012, 32, 988-997.	2.6	4
100	Complexity of Medication Use in Newly Diagnosed Chronic Obstructive Pulmonary Disease Patients. American Journal of Geriatric Pharmacotherapy, 2012, 10, 110-122.e1.	3.0	10
101	Asthma outcomes: Healthcare utilization and costs. Journal of Allergy and Clinical Immunology, 2012, 129, S49-S64.	2.9	88
102	Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: AÂnested case-control study. Journal of Allergy and Clinical Immunology, 2012, 130, 368-375.	2.9	51
103	Cost-effectiveness of influenza vaccination of older adults in the ED setting. American Journal of Emergency Medicine, 2012, 30, 1072-1079.	1.6	14
104	Risk factors and outcomes associated with vancomycin-resistant Enterococcus infections with reduced susceptibilities to linezolid. Diagnostic Microbiology and Infectious Disease, 2012, 74, 39-42.	1.8	16
105	The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999–2008. BMC Pulmonary Medicine, 2012, 12, 26.	2.0	212
106	Trends in anemia management in lung and colon cancer patients in the US Department of Veterans Affairs, 2002–2008. Supportive Care in Cancer, 2012, 20, 1649-1657.	2,2	15
107	Association between Leukotriene-Modifying Agents and Suicide. Drug Safety, 2011, 34, 533-544.	3.2	43
108	Relationship between leukotriene-modifying agent prescriptions dispensed and rate of suicide deaths by county in the US. Drug, Healthcare and Patient Safety, 2011, 3, 47.	2.5	11

#	Article	IF	Citations
109	Life-Years Gained with Meropenem over Ciprofloxacin in Penicillin-Allergic Patients with Gram-Negative Bacilli Sepsis: Results of a Probabilistic Model. Pharmacotherapy, 2011, 31, 469-479.	2.6	3
110	Trends in induction of labor at early-term gestation. American Journal of Obstetrics and Gynecology, 2011, 204, 435.e1-435.e6.	1.3	34
111	National trends and racial differences in late preterm induction. American Journal of Obstetrics and Gynecology, 2011, 205, 458.e1-458.e7.	1.3	8
112	Determinants of Spirometry Use and Accuracy of COPD Diagnosis in Primary Care. Journal of General Internal Medicine, 2011, 26, 1272-1277.	2.6	41
113	The validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary disease. BMC Health Services Research, 2011, 11, 37.	2.2	116
114	Comparison of health-related quality of life measures in chronic obstructive pulmonary disease. Health and Quality of Life Outcomes, 2011, 9, 26.	2.4	73
115	Significant Jâ€shaped association between body mass index (BMI) and diabetic foot ulcers. Diabetes/Metabolism Research and Reviews, 2011, 27, 402-409.	4.0	52
116	Using A Pharmacy-Based Intervention To Improve Antipsychotic Adherence Among Patients With Serious Mental Illness. Schizophrenia Bulletin, 2011, 37, 727-736.	4.3	73
117	Comparative Effectiveness of Paricalcitol versus Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. Nephron Clinical Practice, 2011, 117, c151-c159.	2.3	7
118	Statistical implications of utility weighted and equally weighted HRQL measures: an empirical study. Health Economics (United Kingdom), 2010, 19, 101-110.	1.7	16
119	Safety of Ipratropium Bromide: Response. Chest, 2010, 138, 235-236.	0.8	0
120	Cardiovascular Events Associated With Ipratropium Bromide in COPD. Chest, 2010, 137, 13-19.	0.8	100
121	Hospitalizations for Acute Exacerbations of Chronic Obstructive Pulmonary Disease: How You Count Matters. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2010, 7, 164-171.	1.6	41
122	Lower-Extremity Amputation Risk After Charcot Arthropathy and Diabetic Foot Ulcer. Diabetes Care, 2010, 33, 98-100.	8.6	186
123	Surgery and Adjuvant Chemotherapy Use Among Veterans With Colon Cancer: Insights From a California Study. Journal of Clinical Oncology, 2010, 28, 2571-2576.	1.6	13
124	Defining an Episode of Care for Colonoscopy: Work of the High Value Health Care Project Characterizing Episodes and Costs of Care. Gastrointestinal Endoscopy Clinics of North America, 2010, 20, 735-750.	1.4	1
125	Antibiotic Prescribing for Acute Respiratory Infection and Subsequent Outpatient and Hospital Utilization in Veterans With Spinal Cord Injury and Disorder. PM and R, 2010, 2, 101-109.	1.6	5
126	Diagnostic accuracy of existing methods for identifying diabetic foot ulcers from inpatient and outpatient datasets. Journal of Foot and Ankle Research, 2010, 3, 27.	1.9	27

#	Article	IF	CITATIONS
127	Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respiratory Medicine, 2010, 104, 246-252.	2.9	62
128	Impact of asthma controller medications on medical and economic resource utilization in adult asthma patients. Current Medical Research and Opinion, 2010, 26, 2851-2860.	1.9	19
129	Mortality Risk of Charcot Arthropathy Compared With That of Diabetic Foot Ulcer and Diabetes Alone. Diabetes Care, 2009, 32, 816-821.	8.6	147
130	Cost-effectiveness analysis of an antimicrobial stewardship team on bloodstream infections: a probabilistic analysis. Journal of Antimicrobial Chemotherapy, 2009, 63, 816-825.	3.0	74
131	Coded Cause of Death and Timing of COPD Diagnosis. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 41-47.	1.6	1
132	Mortality Risk in Patients Receiving Drug Regimens with Theophylline for Chronic Obstructive Pulmonary Disease. Pharmacotherapy, 2009, 29, 1039-1053.	2.6	23
133	A Patient-Based Utility Measure of Health for Clinical Trials of Cancer Therapy Based on the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. Value in Health, 2009, 12, 977-988.	0.3	22
134	Medication adherence and persistence in the last year of life in COPD patients. Respiratory Medicine, 2009, 103, 525-534.	2.9	47
135	Use of spirometry in the diagnosis of chronic obstructive pulmonary disease and efforts to improve quality of care. Translational Research, 2009, 154, 103-110.	5. 0	23
136	Vitamin D Deficiency/Insufficiency Practice Patterns in a Veterans Health Administration Long-Term Care Population: A Retrospective Analysis. Journal of the American Medical Directors Association, 2009, 10, 653-657.	2.5	55
137	Obstetricians' Rising Liability Insurance Premiums and Inductions at Late Preterm Gestations. Medical Care, 2009, 47, 425-430.	2.4	18
138	Outcomes Associated With Tiotropium Use in Patients With Chronic Obstructive Pulmonary Disease. Archives of Internal Medicine, 2009, 169, 1403.	3.8	46
139	Effect of Depression Care on Outcomes in COPD Patients With Depression. Chest, 2009, 135, 626-632.	0.8	28
140	Patterns of Healthcare Utilization by COPD Severity: A Pilot Study. Lung, 2008, 186, 307-312.	3.3	17
141	Sixtyâ€four–slice Computed Tomography of the Coronary Arteries: Cost–Effectiveness Analysis of Patients Presenting to the Emergency Department with Lowâ€risk Chest Pain. Academic Emergency Medicine, 2008, 15, 623-632.	1.8	57
142	Charcot Arthropathy Risk Elevation in the Obese Diabetic Population. American Journal of Medicine, 2008, 121, 1008-1014.	1.5	80
143	Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respiratory Medicine, 2008, 102, 519-536.	2.9	126
144	Medication Use Patterns Associated with Spirometry in Diagnosing COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2008, 5, 360-368.	1.6	7

#	Article	IF	Citations
145	Risk for Death Associated with Medications for Recently Diagnosed Chronic Obstructive Pulmonary Disease. Annals of Internal Medicine, 2008, 149, 380.	3.9	151
146	Geographic Variation of Spirometry Use in Newly Diagnosed COPD*. Chest, 2008, 134, 38-45.	0.8	68
147	Racial Disparities in Term Induction of Labor Rates in Illinois. Medical Care, 2008, 46, 900-904.	2.4	8
148	Agreement between Caregiver Reported Healthcare Utilization and Administrative Data for Children with Asthma. Journal of Asthma, 2007, 44, 189-194.	1.7	15
149	Effect of Increased Copayments on Pharmacy Use in the Department of Veterans Affairs. Medical Care, 2007, 45, 1090-1097.	2.4	21
150	Association Between Rising Professional Liability Insurance Premiums and Primary Cesarean Delivery Rates. Obstetrics and Gynecology, 2007, 110, 1264-1269.	2.4	57
151	Impact of NSAIDS on Mortality and the Effect of Preexisting Coronary Artery Disease in US Veterans. American Journal of Medicine, 2007, 120, 98.e9-98.e16.	1.5	28
152	Osteoarthritis: A Comorbid Marker for Longer Life?. Annals of Epidemiology, 2007, 17, 380-384.	1.9	24
153	International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. Lancet, The, 2007, 370, 741-750.	13.7	1,818
154	Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Medicine, 2007, 5, 20.	5.5	334
155	Meta-Analysis of Azelastine Nasal Spray for the Treatment of Allergic Rhinitis. Pharmacotherapy, 2007, 27, 852-859.	2.6	28
156	Impact of Pneumococcal Vaccination on Pneumonia Rates in Patients with COPD and Asthma. Journal of General Internal Medicine, 2007, 22, 62-67.	2.6	64
157	Mortality Rate in Veterans with Multiple Chronic Conditions. Journal of General Internal Medicine, 2007, 22, 403-7.	2.6	127
158	Multiple Chronic Conditions: Prevalence, Health Consequences, and Implications for Quality, Care Management, and Costs. Journal of General Internal Medicine, 2007, 22, 391-395.	2.6	896
159	Effect of Care Setting on Evidence-based Depression Treatment for Veterans with COPD and Comorbid Depression. Journal of General Internal Medicine, 2007, 22, 1447-1452.	2.6	30
160	Geographic Variation in Chronic Obstructive Pulmonary Disease Exacerbation Rates. Journal of General Internal Medicine, 2007, 22, 1560-1565.	2.6	24
161	Spirometry Use in Clinical Practice Following Diagnosis of COPD. Chest, 2006, 129, 1509-1515.	0.8	120
162	Economic Modeling in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2006, 3, 630-634.	3.5	31

#	Article	IF	CITATIONS
163	Assessment of the emergence of Alzheimer's disease following coronary artery bypass graft surgery or percutaneous transluminal coronary angioplasty1. Journal of Alzheimer's Disease, 2005, 7, 319-324.	2.6	171
164	Consensus. Clinical Pulmonary Medicine, 2005, 12, S22-S23.	0.3	0
165	A Multisite Randomized Trial of the Effects of Physician Education and Organizational Change in Chronic Asthma Care. JAMA Pediatrics, 2005, 159, 428.	3.0	62
166	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 277-283.	1.6	256
167	Development of the multi-attribute Pediatric Asthma Health Outcome Measure (PAHOM). International Journal for Quality in Health Care, 2005, 17, 23-30.	1.8	58
168	Three Surveillance Strategies for Vancomycin-Resistant Enterococci in Hospitalized Patients: Detection of Colonization Efficiency and a Cost-Effectiveness Model. Infection Control and Hospital Epidemiology, 2005, 26, 39-46.	1.8	21
169	Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?. Health and Quality of Life Outcomes, 2005, 3, 11.	2.4	51
170	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2005, 2, 277-283.	1.6	8
171	Fracture Risk Associated with Inhaled Corticosteroid Use in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 855-859.	5.6	92
172	Chronic Heart Failure–Related Interventions After Starting Rosiglitazone in Patients Receiving Insulin. Pharmacotherapy, 2004, 24, 1317-1322.	2.6	21
173	The Economic Burden of Allergic Rhinitis. Pharmacoeconomics, 2004, 22, 345-361.	3.3	182
174	Cost-effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease. American Journal of Medicine, 2004, 117, 618.	1.5	1
175	Cost of Chronic Hepatitis B Infection in the United States. Journal of Clinical Gastroenterology, 2004, 38, S144-S147.	2.2	49
176	Evaluating the efficiency of treatment in the allergic rhinitis market. Journal of Managed Care Pharmacy, 2004, 10, S3-8.	2.2	1
177	Comparison of Directly Elicited Preferences to Preferences Derived from the SF-36 in Adults with Asthma. Medical Decision Making, 2003, 23, 323-334.	2.4	28
178	Preference assessment in patients with asthma. Expert Review of Pharmacoeconomics and Outcomes Research, 2002, 2, 607-618.	1.4	4
179	An update on the health economics of asthma and allergy. Current Opinion in Allergy and Clinical Immunology, 2002, 2, 195-200.	2.3	7
180	The Economic Burden of COPD. Chest, 2000, 117, 5S-9S.	0.8	507